The TNF superfamily in 2009: new pathways, new indications, and new drugs
Today's most successful class of biologics targets the inflammatory cytokine tumor necrosis factor in autoimmune diseases including rheumatoid arthritis, psoriasis and Crohn's. With five anti-TNF biologics now on the market, attention has turned toward novel strategies to improve the safet...
Gespeichert in:
| Veröffentlicht in: | Drug discovery today 2009-12, Vol.14 (23-24), p.1082-1088 |
|---|---|
| Hauptverfasser: | , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1088 |
|---|---|
| container_issue | 23-24 |
| container_start_page | 1082 |
| container_title | Drug discovery today |
| container_volume | 14 |
| creator | Tansey, Malú G. Szymkowski, David E. |
| description | Today's most successful class of biologics targets the inflammatory cytokine tumor necrosis factor in autoimmune diseases including rheumatoid arthritis, psoriasis and Crohn's. With five anti-TNF biologics now on the market, attention has turned toward novel strategies to improve the safety and efficacy of next-generation TNF inhibitors. Beyond TNF, drugs are under development that modulate many other ligands and receptors of the TNF superfamily. Biologics targeting at least 16 of the approximately 22 known ligand–receptor pairs are now in clinical development for autoimmune diseases, cancers and osteoporosis. A deeper understanding of intracellular signaling has also facilitated small-molecule interventions, opening the door to oral therapies. This report summarizes recent developments in this highly druggable superfamily, including highlights of the latest international TNF conference. |
| doi_str_mv | 10.1016/j.drudis.2009.10.002 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_877571736</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1359644609003377</els_id><sourcerecordid>733785286</sourcerecordid><originalsourceid>FETCH-LOGICAL-c457t-4bb09ef91085f872e048fb05040405a329c967971857055b7d33299e481be0e13</originalsourceid><addsrcrecordid>eNqNkcFPwjAUxhujEUT_A2N28-KwXdu19WBiiCgJ0Quem257kxLYsN0k_Pd2QOJNSQ9tv_ze-17eh9A1wUOCSXq_GBauLawfJhirIA0xTk5Qn0ghYy5pchrelKs4ZSztoQvvFxiTRPH0HPWIklQQmfbRZDaHaPY2jny7BlealV1uI1tFXdOHqIJNtDbNfGO2_m73s1Vhc9PYugqCqYqdGAb59JforDRLD1eHe4A-xs-z0Ws8fX-ZjJ6mcc64aGKWZVhBqQiWvJQiAcxkmWGOWTjc0ETlKhUqTMcF5jwTBQ2aAiZJBhgIHaDbfd-1q79a8I1eWZ_DcmkqqFuvpRBcEEHTo8hUMUWPJAlj_5KCUiF5Ijt3tidzV3vvoNRrZ1fGbTXBuktQL_Q-Qd0tu1NDgqHs5mDQZisofosOkQXgcQ9AWPK3Bad9bqHKobAO8kYXtf3b4QdfH6og</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>733785286</pqid></control><display><type>article</type><title>The TNF superfamily in 2009: new pathways, new indications, and new drugs</title><source>MEDLINE</source><source>Access via ScienceDirect (Elsevier)</source><creator>Tansey, Malú G. ; Szymkowski, David E.</creator><creatorcontrib>Tansey, Malú G. ; Szymkowski, David E.</creatorcontrib><description>Today's most successful class of biologics targets the inflammatory cytokine tumor necrosis factor in autoimmune diseases including rheumatoid arthritis, psoriasis and Crohn's. With five anti-TNF biologics now on the market, attention has turned toward novel strategies to improve the safety and efficacy of next-generation TNF inhibitors. Beyond TNF, drugs are under development that modulate many other ligands and receptors of the TNF superfamily. Biologics targeting at least 16 of the approximately 22 known ligand–receptor pairs are now in clinical development for autoimmune diseases, cancers and osteoporosis. A deeper understanding of intracellular signaling has also facilitated small-molecule interventions, opening the door to oral therapies. This report summarizes recent developments in this highly druggable superfamily, including highlights of the latest international TNF conference.</description><identifier>ISSN: 1359-6446</identifier><identifier>EISSN: 1878-5832</identifier><identifier>DOI: 10.1016/j.drudis.2009.10.002</identifier><identifier>PMID: 19837186</identifier><language>eng</language><publisher>England: Elsevier Ltd</publisher><subject>Autoimmune Diseases - drug therapy ; Autoimmune Diseases - immunology ; Autoimmune Diseases - metabolism ; Drug Discovery ; Humans ; Neoplasms - drug therapy ; Neoplasms - immunology ; Neoplasms - metabolism ; Osteoporosis - drug therapy ; Osteoporosis - immunology ; Osteoporosis - metabolism ; Tumor Necrosis Factors - antagonists & inhibitors ; Tumor Necrosis Factors - physiology</subject><ispartof>Drug discovery today, 2009-12, Vol.14 (23-24), p.1082-1088</ispartof><rights>2009 Elsevier Ltd</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c457t-4bb09ef91085f872e048fb05040405a329c967971857055b7d33299e481be0e13</citedby><cites>FETCH-LOGICAL-c457t-4bb09ef91085f872e048fb05040405a329c967971857055b7d33299e481be0e13</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.drudis.2009.10.002$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>310,311,315,781,785,790,791,3551,23932,23933,25142,27926,27927,45997</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/19837186$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Tansey, Malú G.</creatorcontrib><creatorcontrib>Szymkowski, David E.</creatorcontrib><title>The TNF superfamily in 2009: new pathways, new indications, and new drugs</title><title>Drug discovery today</title><addtitle>Drug Discov Today</addtitle><description>Today's most successful class of biologics targets the inflammatory cytokine tumor necrosis factor in autoimmune diseases including rheumatoid arthritis, psoriasis and Crohn's. With five anti-TNF biologics now on the market, attention has turned toward novel strategies to improve the safety and efficacy of next-generation TNF inhibitors. Beyond TNF, drugs are under development that modulate many other ligands and receptors of the TNF superfamily. Biologics targeting at least 16 of the approximately 22 known ligand–receptor pairs are now in clinical development for autoimmune diseases, cancers and osteoporosis. A deeper understanding of intracellular signaling has also facilitated small-molecule interventions, opening the door to oral therapies. This report summarizes recent developments in this highly druggable superfamily, including highlights of the latest international TNF conference.</description><subject>Autoimmune Diseases - drug therapy</subject><subject>Autoimmune Diseases - immunology</subject><subject>Autoimmune Diseases - metabolism</subject><subject>Drug Discovery</subject><subject>Humans</subject><subject>Neoplasms - drug therapy</subject><subject>Neoplasms - immunology</subject><subject>Neoplasms - metabolism</subject><subject>Osteoporosis - drug therapy</subject><subject>Osteoporosis - immunology</subject><subject>Osteoporosis - metabolism</subject><subject>Tumor Necrosis Factors - antagonists & inhibitors</subject><subject>Tumor Necrosis Factors - physiology</subject><issn>1359-6446</issn><issn>1878-5832</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2009</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkcFPwjAUxhujEUT_A2N28-KwXdu19WBiiCgJ0Quem257kxLYsN0k_Pd2QOJNSQ9tv_ze-17eh9A1wUOCSXq_GBauLawfJhirIA0xTk5Qn0ghYy5pchrelKs4ZSztoQvvFxiTRPH0HPWIklQQmfbRZDaHaPY2jny7BlealV1uI1tFXdOHqIJNtDbNfGO2_m73s1Vhc9PYugqCqYqdGAb59JforDRLD1eHe4A-xs-z0Ws8fX-ZjJ6mcc64aGKWZVhBqQiWvJQiAcxkmWGOWTjc0ETlKhUqTMcF5jwTBQ2aAiZJBhgIHaDbfd-1q79a8I1eWZ_DcmkqqFuvpRBcEEHTo8hUMUWPJAlj_5KCUiF5Ijt3tidzV3vvoNRrZ1fGbTXBuktQL_Q-Qd0tu1NDgqHs5mDQZisofosOkQXgcQ9AWPK3Bad9bqHKobAO8kYXtf3b4QdfH6og</recordid><startdate>200912</startdate><enddate>200912</enddate><creator>Tansey, Malú G.</creator><creator>Szymkowski, David E.</creator><general>Elsevier Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>7QO</scope><scope>8FD</scope><scope>FR3</scope><scope>P64</scope></search><sort><creationdate>200912</creationdate><title>The TNF superfamily in 2009: new pathways, new indications, and new drugs</title><author>Tansey, Malú G. ; Szymkowski, David E.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c457t-4bb09ef91085f872e048fb05040405a329c967971857055b7d33299e481be0e13</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2009</creationdate><topic>Autoimmune Diseases - drug therapy</topic><topic>Autoimmune Diseases - immunology</topic><topic>Autoimmune Diseases - metabolism</topic><topic>Drug Discovery</topic><topic>Humans</topic><topic>Neoplasms - drug therapy</topic><topic>Neoplasms - immunology</topic><topic>Neoplasms - metabolism</topic><topic>Osteoporosis - drug therapy</topic><topic>Osteoporosis - immunology</topic><topic>Osteoporosis - metabolism</topic><topic>Tumor Necrosis Factors - antagonists & inhibitors</topic><topic>Tumor Necrosis Factors - physiology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Tansey, Malú G.</creatorcontrib><creatorcontrib>Szymkowski, David E.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>Biotechnology Research Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><jtitle>Drug discovery today</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Tansey, Malú G.</au><au>Szymkowski, David E.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The TNF superfamily in 2009: new pathways, new indications, and new drugs</atitle><jtitle>Drug discovery today</jtitle><addtitle>Drug Discov Today</addtitle><date>2009-12</date><risdate>2009</risdate><volume>14</volume><issue>23-24</issue><spage>1082</spage><epage>1088</epage><pages>1082-1088</pages><issn>1359-6446</issn><eissn>1878-5832</eissn><abstract>Today's most successful class of biologics targets the inflammatory cytokine tumor necrosis factor in autoimmune diseases including rheumatoid arthritis, psoriasis and Crohn's. With five anti-TNF biologics now on the market, attention has turned toward novel strategies to improve the safety and efficacy of next-generation TNF inhibitors. Beyond TNF, drugs are under development that modulate many other ligands and receptors of the TNF superfamily. Biologics targeting at least 16 of the approximately 22 known ligand–receptor pairs are now in clinical development for autoimmune diseases, cancers and osteoporosis. A deeper understanding of intracellular signaling has also facilitated small-molecule interventions, opening the door to oral therapies. This report summarizes recent developments in this highly druggable superfamily, including highlights of the latest international TNF conference.</abstract><cop>England</cop><pub>Elsevier Ltd</pub><pmid>19837186</pmid><doi>10.1016/j.drudis.2009.10.002</doi><tpages>7</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1359-6446 |
| ispartof | Drug discovery today, 2009-12, Vol.14 (23-24), p.1082-1088 |
| issn | 1359-6446 1878-5832 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_877571736 |
| source | MEDLINE; Access via ScienceDirect (Elsevier) |
| subjects | Autoimmune Diseases - drug therapy Autoimmune Diseases - immunology Autoimmune Diseases - metabolism Drug Discovery Humans Neoplasms - drug therapy Neoplasms - immunology Neoplasms - metabolism Osteoporosis - drug therapy Osteoporosis - immunology Osteoporosis - metabolism Tumor Necrosis Factors - antagonists & inhibitors Tumor Necrosis Factors - physiology |
| title | The TNF superfamily in 2009: new pathways, new indications, and new drugs |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-18T02%3A16%3A25IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20TNF%20superfamily%20in%202009:%20new%20pathways,%20new%20indications,%20and%20new%20drugs&rft.jtitle=Drug%20discovery%20today&rft.au=Tansey,%20Mal%C3%BA%20G.&rft.date=2009-12&rft.volume=14&rft.issue=23-24&rft.spage=1082&rft.epage=1088&rft.pages=1082-1088&rft.issn=1359-6446&rft.eissn=1878-5832&rft_id=info:doi/10.1016/j.drudis.2009.10.002&rft_dat=%3Cproquest_cross%3E733785286%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=733785286&rft_id=info:pmid/19837186&rft_els_id=S1359644609003377&rfr_iscdi=true |